Table 6. Time course of changes in the types of ophthalmic solutions administered to nonfailure eyes of the phaco and medication groups.
| Group | Types of ophthalmic solutions | Time following treatment | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 3 mon | 6 mon | 9 mon | 1 yr | 1.5 yr | 2 yr | 2.5 yr | 3 yr | ||
| Phaco group | Anti-inflammatories | 39/50 (78.0) | 35/44 (79.5) | 22/38 (57.9) | 20/34 (58.8) | 9/21 (42.9) | 7/15 (46.7) | 2/12 (16.7) | 1/8 (12.5) |
| Corticosteroids | 7/39 (17.9) | 4/35 (11.4) | 4/22 (18.2) | 5/20 (25.0) | 2/9 (22.2) | 0/15 (0.0) | 0/12 (0.0) | 0/8 (0.0) | |
| NSAIDs | 32/39 (82.1) | 31/35 (88.6) | 18/22 (81.8) | 15/20 (75.0) | 7/9 (77.8) | 7/7 (100.0) | 2/2 (100.0) | 1/1 (100.0) | |
| Lacrimostimulants | 38/50 (76.0) | 22/44 (50.0) | 20/38 (52.6) | 18/34 (52.9) | 10/21 (47.6) | 10/15 (66.7) | 7/12 (58.3) | 3/8 (37.5) | |
| Hyperosmotic agents | 4/50 (8.0) | 2/44 (4.5) | 4/38 (10.5) | 5/34 (14.7) | 3/21 (14.3) | 1/15 (6.7) | 0/12 (0.0) | 0/8 (0.0) | |
| Antibiotics | 4/50 (8.0) | 0/44 (0.0) | 0/38 (0.0) | 1/34 (2.9) | 0/21 (0.0) | 2/15 (13.3) | 0/12 (0.0) | 0/8 (0.0) | |
| Ocular hypotensive agents | 2/50 (4.0) | 2/44 (4.5) | 2/38 (5.3) | 1/34 (2.9) | 0/21 (0.0) | 0/15 (0.0) | 3/12 (25.0) | 3/8 (37.5) | |
| EDTA | 1/50 (2.0) | 1/44 (2.3) | 1/38 (2.6) | 1/34 (2.9) | 0/21 (0.0) | 0/15 (0.0) | 1/12 (8.3) | 0/8 (0.0) | |
| Mydriatics | 0/50 (0.0) | 2/44 (4.5) | 0/38 (0.0) | 1/34 (2.9) | 0/21 (0.0) | 1/15 (6.7) | 0/12 (0.0) | 0/8 (0.0) | |
| Allogenic serum | 0/50 (0.0) | 0/44 (0.0) | 0/38 (0.0) | 1/34 (2.9) | 0/21 (0.0) | 1/15 (6.7) | 0/12 (0.0) | 0/8 (0.0) | |
| Medication group | Anti-inflammatories | 64/69 (92.8) | 36/40 (90.0) | 32/35 (91.4) | 22/25 (88.0) | 10/14 (71.4) | 7/8 (87.5) | 7/8 (87.5) | 5/7 (71.4) |
| Corticosteroids | 4/64 (6.3) | 0/36 (0.0) | 3/32 (9.4) | 0/22 (0.0) | 0/10 (0.0) | 0/7 (0.0) | 0/7 (0.0) | 0/5 (0.0) | |
| NSAIDs | 64/64 (100.0) | 36/36 (100.0) | 31/32 (96.9) | 22/22 (100.0) | 10/10 (100.0) | 7/7 (100.0) | 7/7 (100.0) | 5/5 (100.0) | |
| Lacrimostimulants | 28/69 (40.6) | 20/40 (50.0) | 19/35 (54.3) | 15/25 (60.0) | 9/14 (64.3) | 4/8 (50.0) | 4/8 (50.0) | 4/7 (57.1) | |
| Hyperosmotic agents | 0/69 (0.0) | 0/40 (0.0) | 0/35 (0.0) | 2/25 (8.0) | 2/14 (14.3) | 0/8 (0.0) | 1/8 (12.5) | 2/7 (28.6) | |
| Antibiotics | 13/69 (18.8) | 11/40 (27.5) | 9/35 (25.7) | 8/25 (32.0) | 4/14 (28.6) | 4/8 (50.0) | 5/8 (62.5) | 4/7 (57.1) | |
| Ocular hypotensive agents | 3/69 (4.3) | 4/40 (10.0) | 4/35 (11.4) | 2/25 (8.0) | 2/14 (14.3) | 2/8 (25.0) | 3/8 (37.5) | 3/7 (42.9) | |
| EDTA | 3/69 (4.3) | 4/40 (10.0) | 3/35 (8.6) | 4/25 (16.0) | 2/14 (14.3) | 0/8 (0.0) | 0/8 (0.0) | 0/7 (0.0) | |
| Mydriatics | 6/69 (8.7) | 6/40 (15.0) | 2/35 (5.7) | 4/25 (16.0) | 2/14 (14.3) | 2/8 (25.0) | 2/8 (25.0) | 0/7 (0.0) | |
| Allogenic serum | 0/69 (0.0) | 1/40 (2.5) | 0/35 (0.0) | 3/25 (12.0) | 1/14 (7.1) | 0/8 (0.0) | 0/8 (0.0) | 0/7 (0.0) | |
Types of ophthalmic solutions were recorded for the eyes with available follow-up data at each time point. Values are presented as number of eyes (%).
NSAIDs, nonsteroidal anti-inflammatory drugs; EDTA, ethylenediaminetetraacetic acid.